Search research articles
Contact Us
Filters
Showing results (81-90 of 107) with videos related to
Page
of 11
Sort By:
Journal of the American College of Cardiology
|
May 20, 2021
Effect of Ejection Fraction on Clinical Outcomes in Patients Treated With Omecamtiv Mecarbil in GALACTIC-HF
John R Teerlink, Rafael Diaz, G Michael Felker, et al.
ESC Heart Failure
|
February 19, 2026
Efficacy of aficamten according to geographic location of patients with hypertrophic obstructive cardiomyopathy
Caroline J Coats, Theodore Abraham, Roberto Barriales-Villa, et al.
Journal of the American College of Cardiology
|
May 30, 2020
Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy
Carolyn Y Ho, Matthew E Mealiffe, Richard G Bach, et al.
Journal of Cardiac Failure
|
September 30, 2025
Safety and Efficacy of Aficamten in Patients With Nonobstructive Hypertrophic Cardiomyopathy: A 96-Week Analysis From FOREST-HCM
Ahmad Masri, Mark V Sherrid, Lubna Choudhury, et al.
Journal of the American College of Cardiology
|
October 30, 2024
Standard-of-Care Medication Withdrawal in Patients With Obstructive Hypertrophic Cardiomyopathy Receiving Aficamten in FOREST-HCM
Ahmad Masri, Lubna Choudhury, Roberto Barriales-Villa, et al.
Journal of the American College of Cardiology
|
September 1, 2024
Impact of Aficamten on Echocardiographic Cardiac Structure and Function in Symptomatic Obstructive Hypertrophic Cardiomyopathy
Sheila M Hegde, Brian L Claggett, Xiaowen Wang, et al.
JACC. Heart Failure
|
February 5, 2025
Aficamten vs Metoprolol for Obstructive Hypertrophic Cardiomyopathy: MAPLE-HCM Rationale, Study Design, and Baseline Characteristics
Pablo Garcia-Pavia, Ozlem Bilen, Melissa Burroughs, et al.
JAMA Cardiology
|
September 4, 2024
Aficamten and Cardiopulmonary Exercise Test Performance: A Substudy of the SEQUOIA-HCM Randomized Clinical Trial
Matthew M Y Lee, Ahmad Masri, Michael E Nassif, et al.
European Heart Journal
|
September 1, 2024
Cardiac biomarkers and effects of aficamten in obstructive hypertrophic cardiomyopathy: the SEQUOIA-HCM trial
Caroline J Coats, Ahmad Masri, Roberto Barriales-Villa, et al.
JACC. Heart Failure
|
June 20, 2025
Aficamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy: 48-Week Results From FOREST-HCM
Sara Saberi, Theodore P Abraham, Lubna Choudhury, et al.
Page
of 11
Search research articles
Search
Showing results (81-90 of 107) with videos related to
Sort By:
Page
of 11
Journal of the American College of Cardiology
|
May 20, 2021
Effect of Ejection Fraction on Clinical Outcomes in Patients Treated With Omecamtiv Mecarbil in GALACTIC-HF
John R Teerlink, Rafael Diaz, G Michael Felker, et al.
ESC Heart Failure
|
February 19, 2026
Efficacy of aficamten according to geographic location of patients with hypertrophic obstructive cardiomyopathy
Caroline J Coats, Theodore Abraham, Roberto Barriales-Villa, et al.
Journal of the American College of Cardiology
|
May 30, 2020
Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy
Carolyn Y Ho, Matthew E Mealiffe, Richard G Bach, et al.
Journal of Cardiac Failure
|
September 30, 2025
Safety and Efficacy of Aficamten in Patients With Nonobstructive Hypertrophic Cardiomyopathy: A 96-Week Analysis From FOREST-HCM
Ahmad Masri, Mark V Sherrid, Lubna Choudhury, et al.
Journal of the American College of Cardiology
|
October 30, 2024
Standard-of-Care Medication Withdrawal in Patients With Obstructive Hypertrophic Cardiomyopathy Receiving Aficamten in FOREST-HCM
Ahmad Masri, Lubna Choudhury, Roberto Barriales-Villa, et al.
Journal of the American College of Cardiology
|
September 1, 2024
Impact of Aficamten on Echocardiographic Cardiac Structure and Function in Symptomatic Obstructive Hypertrophic Cardiomyopathy
Sheila M Hegde, Brian L Claggett, Xiaowen Wang, et al.
JACC. Heart Failure
|
February 5, 2025
Aficamten vs Metoprolol for Obstructive Hypertrophic Cardiomyopathy: MAPLE-HCM Rationale, Study Design, and Baseline Characteristics
Pablo Garcia-Pavia, Ozlem Bilen, Melissa Burroughs, et al.
JAMA Cardiology
|
September 4, 2024
Aficamten and Cardiopulmonary Exercise Test Performance: A Substudy of the SEQUOIA-HCM Randomized Clinical Trial
Matthew M Y Lee, Ahmad Masri, Michael E Nassif, et al.
European Heart Journal
|
September 1, 2024
Cardiac biomarkers and effects of aficamten in obstructive hypertrophic cardiomyopathy: the SEQUOIA-HCM trial
Caroline J Coats, Ahmad Masri, Roberto Barriales-Villa, et al.
JACC. Heart Failure
|
June 20, 2025
Aficamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy: 48-Week Results From FOREST-HCM
Sara Saberi, Theodore P Abraham, Lubna Choudhury, et al.
Page
of 11